Shingo Iwami

InstitutionKyushu University
AddressFukuoka
Japan
vCardDownload vCard
    Publication Timeline
    COVID-19 publications
    Bar chart showing 10 Covid-19 publications, with a maximum of 3 publications in March 2021 and April 2021
    All Publications
    Bar chart showing 55 publications over 14 distinct years, with a maximum of 10 publications in 2021
    These graphs show COVID-19 publications by month since August 2019 and all publications written by authors of COVID-19 publications over the past 30 years.

    To see the data from both graphs as text, click here.
    Publication Field Summary
    This graph shows the number and percent of publications by field. Fields are based on how the National Library of Medicine (NLM) classifies the publications' journals and might not represent the specific topics of the publications. Note that an individual publication can be assigned to more than one field. As a result, the publication counts in this graph might add up to more than the number of publications the person has written. To see the data as text, click here.
    Publication List
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications.
    Sort By:     Newest   |   Oldest   |   Most Cited   |   Most Discussed
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Kim KS, Iwanami S, Oda T, Fujita Y, Kuba K, Miyazaki T, Ejima K, Iwami S. Incomplete antiviral treatment may induce longer durations of viral shedding during SARS-CoV-2 infection. Life Sci Alliance. 2021 10; 4(10). PMID: 34344719.
      Citations:    Fields:    Translation:Animals
    2. Jeong YD, Ejima K, Kim KS, Iwanami S, Bento AI, Fujita Y, Jung IH, Aihara K, Watashi K, Miyazaki T, Wakita T, Iwami S, Ajelli M. Revisiting the guidelines for ending isolation for COVID-19 patients. Elife. 2021 07 27; 10. PMID: 34311842.
      Citations:    Fields:    Translation:HumansPHPublic Health
    3. Iwanami S, Ejima K, Kim KS, Noshita K, Fujita Y, Miyazaki T, Kohno S, Miyazaki Y, Morimoto S, Nakaoka S, Koizumi Y, Asai Y, Aihara K, Watashi K, Thompson RN, Shibuya K, Fujiu K, Perelson AS, Iwami S, Wakita T. Detection of significant antiviral drug effects on COVID-19 with reasonable sample sizes in randomized controlled trials: A modeling study. PLoS Med. 2021 07; 18(7):e1003660. PMID: 34228712.
      Citations: 4     Fields:    Translation:Humans
    4. Ejima K, Koizumi Y, Yamamoto N, Rosenberg M, Ludema C, Bento AI, Yoneoka D, Ichikawa S, Mizushima D, Iwami S. HIV Testing by Public Health Centers and Municipalities and New HIV Cases During the COVID-19 Pandemic in Japan. J Acquir Immune Defic Syndr. 2021 06 01; 87(2):e182-e187. PMID: 33625066.
      Citations: 4     Fields:    Translation:HumansPHPublic Health
    5. Shionoya K, Yamasaki M, Iwanami S, Ito Y, Fukushi S, Ohashi H, Saso W, Tanaka T, Aoki S, Kuramochi K, Iwami S, Takahashi Y, Suzuki T, Muramatsu M, Takeda M, Wakita T, Watashi K. Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry Inhibitor in vitro. Front Microbiol. 2021; 12:651403. PMID: 33995308.
      Citations: 4     
    6. Hosogaya N, Miyazaki T, Fukushige Y, Takemori S, Morimoto S, Yamamoto H, Hori M, Kurokawa T, Kawasaki Y, Hanawa M, Fujii Y, Hanaoka H, Iwami S, Watashi K, Yamagoe S, Miyazaki Y, Wakita T, Izumikawa K, Yanagihara K, Mukae H, Kohno S. Efficacy and safety of nelfinavir in asymptomatic and mild COVID-19 patients: a structured summary of a study protocol for a multicenter, randomized controlled trial. Trials. 2021 Apr 28; 22(1):309. PMID: 33910617.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    7. Ejima K, Kim KS, Iwanami S, Fujita Y, Li M, Zoh RS, Aihara K, Miyazaki T, Wakita T, Iwami S. Time variation in the probability of failing to detect a case of polymerase chain reaction testing for SARS-CoV-2 as estimated from a viral dynamics model. J R Soc Interface. 2021 04; 18(177):20200947. PMID: 33878277.
      Citations:    Fields:    Translation:Humans
    8. Ohashi H, Watashi K, Saso W, Shionoya K, Iwanami S, Hirokawa T, Shirai T, Kanaya S, Ito Y, Kim KS, Nomura T, Suzuki T, Nishioka K, Ando S, Ejima K, Koizumi Y, Tanaka T, Aoki S, Kuramochi K, Suzuki T, Hashiguchi T, Maenaka K, Matano T, Muramatsu M, Saijo M, Aihara K, Iwami S, Takeda M, McKeating JA, Wakita T. Potential anti-COVID-19 agents, cepharanthine and nelfinavir, and their usage for combination treatment. iScience. 2021 Apr 23; 24(4):102367. PMID: 33817567.
      Citations: 19     
    9. Kim KS, Ejima K, Iwanami S, Fujita Y, Ohashi H, Koizumi Y, Asai Y, Nakaoka S, Watashi K, Aihara K, Thompson RN, Ke R, Perelson AS, Iwami S. A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2. PLoS Biol. 2021 03; 19(3):e3001128. PMID: 33750978.
      Citations: 8     Fields:    Translation:HumansCells
    10. Ejima K, Kim KS, Ludema C, Bento AI, Iwanami S, Fujita Y, Ohashi H, Koizumi Y, Watashi K, Aihara K, Nishiura H, Iwami S. Estimation of the incubation period of COVID-19 using viral load data. Epidemics. 2021 06; 35:100454. PMID: 33773195.
      Citations: 2     Fields:    Translation:Humans